New dual-target drug may help overcome immunotherapy resistance in pancreatic cancer

MedicalXpress | avr. 29, 2026

Pancreatic ductal adenocarcinoma is one of the deadliest cancer types, with a five-year survival rate of 13%. There are only two treatment regimens available with limited efficacy. Pancreatic cancers do not respond to immunotherapy where the body's immune system attacks tumor cells.